A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

Part of paid clinical trials in Chandler, Arizona.

Sponsor
Kriya Therapeutics, Inc.
Study ID
NCT07732400
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • VV-14303 — GENETIC
    will be administered via ultrasound guided intramuscular injections

Study Details

A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)

Key Dates

First listed
Jul 28, 2026
Start date
Jul 30, 2026
Status verified
Aug 2026
Primary completion
Jul 31, 2028
Completion
Jul 31, 2029

Study Design

Enrollment
56 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1 Cohort 1, dose #1
    Dose #1 of VV-14303 will be administered
  • Experimental: Part 1 Cohort 2, dose #2
    Dose #2 of VV-14303 will be administered
  • Experimental: Part 1 Cohort 3, dose #3
    Dose #3 of VV-14303 will be administered
  • Experimental: Part 2 dose
    VV-14303 will be administered at the dose determined from Part 1 (Cohorts 1, 2, and 3)

Primary Outcome Measure

Incidence and severity of adverse events, abnormal clinical laboratory values, abnormal physical exams, abnormal vital signs, abnormal ECGs, and abnormal imaging [ Time Frame: 52 Weeks ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Kriya Clinical Trial SiteChandlerArizona85224
VP, Medical Affairs
[email protected]
1.984.884.5058
Kriya Clinical Trial SiteLady LakeFlorida32159-

Find similar trials in Chandler, AZ

By research site
Kriya Clinical Trial Site· Chandler, AZKriya Clinical Trial Site· Lady Lake, FL

Related Studies